Tuesday, September 06, 2011

Roche, Evotec Ink Pact Worth $830M - Sept. 6, 2011

Having trouble viewing this email? View in Browser.
BioSpace GenePool
   Tuesday, September 06, 2011 Advertising Information
subscriptions careernetwork news hotbeds careerfairs
Facebook  |  Linked In  |  Twitter  |  RSS  |  Subscribe

TOP SPONSOR

UC Berkeley Extension Clinical and Regulatory Sciences

Get the specialized instruction you need to advance your career. UC Berkeley Extension offers targeted certificates and programs to provide the skills to design and manage clinical trials, navigate compliance issues, and ensure new products and processes adhere to U.S. and international regulatory specifications. Choose from programs in:

Clinical Research Conduct and Management (available online)
Quality and Compliance for Biotechnology
Regulatory Affairs

Fall courses are open for enrollment. Learn more.
Top Stories 
•  Roche (RHHBY), Evotec AG (EVTG.F) Ink Pact Worth $830 Million More...
•  Astellas Pharma Inc. (YPH.BE), Evec Team Up for Antibody Pact Worth Up to $176.8 Million More...
•  Sanofi (France) (SASY.PA) Outlines Long-Term Objectives Post Patent Expires, More Cost Cuts to Come More...
•  Biogen Idec, Inc. (Massachusetts) (BIIB) Reclaims Joint Ventures in Italy and Switzerland More...
•  Johnson & Johnson (JNJ), Bayer AG (BAY.F) Fall as FDA Staff Urges Xarelto Not Get Expanded Use More...
•  FDA to Review Safety of Popular Bone Drugs like Merck & Co., Inc. (MRK)'s Fosamax and Roche (RHHBY)'s Boniva More...
•  Vertex Pharmaceuticals Incorporated (VRTX)'s Arthritis Pill Shines in Phase II Study More...
•  Dendreon Corporation (DNDN) Ends Pact With GlaxoSmithKline (GSK) Over Provenge Antigen More...

More Top News
Don't Miss This

PPD Central Labs

Combine the expertise of a leading contract research organization (CRO) with global central laboratories that are among the world's largest dedicated exclusively to clinical trials.

Please click here for more information.
Featured Stories
•  A Grieving Johnson & Johnson (JNJ) Employee And Cubicle Photos More...
•  Death of Medicis (MRX) CEO's Girlfriend Ruled a Suicide More...
•  Breast Cancer Risk Drops When Diet Includes Walnuts, Marshall University School of Medicine Study More...
•  Harmless Soil-Dwelling Bacteria Successfully Kill Cancer, University of York Study More...
•  New HIV Vaccine Approach Targets Desirable Immune Cells, Duke University Medical Center, Beth Israel Deaconess Medical Center and Harvard Medical School Study More...
•  Tick-Borne Parasite Infecting Blood Supply: Centers for Disease Control and Prevention (CDC) Study More...
•  Genes May Influence PTSD, Northern Illinois University Study More...
•  Why Men's Ring Fingers Are Longer Than Their Index Fingers: Male-Female Ring Finger Proportions Tied to Sex Hormones in Embryo, University of Florida Study More...
Tower: Facebook

 
More Featured News
Event of the day

SafeBridge Consultants, Inc. announces two Potent Compound Safety Training offerings (may be taken separately or consecutively)

The SafeBridge original Potent Compound Safety "Boot Camp"® (Boot Camp I) is a comprehensive two-day course in pharmaceutical potent compound safety focused on training EH&S and related professionals in critical technical concepts and proactive safety programs in pharmaceutical industrial hygiene, occupational and environmental toxicology, analytical chemistry, and risk communication.

The SafeBridge Advanced Concepts to Support Drug Development of Potent Compounds from R&D through Manufacturing (Boot Camp II) is a one-day advanced course focused on case studies and problem-solving to address potent compound safety issues in discovery, development, contract manufacturing and commercialization.

COURSE SEATING IS LIMITED AND USUALLY SELLS OUT!

New Brunswick, New Jersey
Boot Camp I September 20 - 21, 2011
Boot Camp II September 22, 2011

Contact: Susan Custer at susan.custer@safebridge.com or 650-961-4820 x 231 or www.safebridge.com
Latest Market Insight

The Stem Cell Market Outlook

• Identify potential growth markets with sales forecasts by indication and expected timing of market entry.
• Compare the different business models for stem cell therapies.
• Evaluate which novel products offer the greatest potential clinical advances over the next several years and why.
• Assess potential clinical advances and how they address current unmet needs.

Click Here for More Information


Featured Free Resource

Nature Methods

Nature Methods provides techniques for life scientists and chemists. It is a print and online publication dedicated to publishing novel methods together with significant advances to tried and tested techniques allowing researchers to perform faster, better and more efficient experimental research.

Request Now!
Top Jobs
Genetown and Bio NC (Billerica, Massachusetts and Durham, North Carolina)

SPARKS
Clinical Trial Specialists
Act as an independent Coordinator on projects both locally and remotely. Apply knowledge across multiple projects. Contribute to the development and implementation of Study Start Up (SSU) related processes, tools, and training materials as well as provide training as needed.

Biotech Bay (Foster City, California)

Gilead Sciences
Senior Director Biomarker Core
Lead a small group of scientists to successfully integrate biomarker strategies and biomarker assays initiated in discovery and translated through to clinical development programs in multiple therapeutic areas.

BioMidwest (New Prague, Minnesota)

Electromed, Inc.
Chief Financial Officer
Responsible for all accounting practices, including the timely completion of the companys accounting and financial reporting. He/She proposes financial strategy, planning, and forecasts in consultation with company officers and managers.

Biotech Beach (Los Angeles, California)

Baxter International, Inc.
Manager, Engineering
Manage a controls system engineering staff and coordinate resources to meet the business needs of all manufacturing and facilities areas. Create and manage a vision for the process control group and systems that aligns with the organization's strategic plan.

BioCapital (Frederick, Maryland)

MedImmune, LLC
QA Specialist III - ATS
Responsible for assuring the quality of licensed products manufactured at MedImmune and contractors. Supports the evaluation and disposition of labeling, raw materials, intermediates and finished products through timely compliance evaluation of batch records, laboratory results and other cGMP documents.

Get Noticed! Add your resume to the BioSpace Career Center!
See more than 5,000 job postings in the BioSpace Career Center!
BioSpace Career Fairs

Biotech Pharm Country Career Fair

Biotech Beach Career Fair

Job seekers can spend a day with HR representatives and Hiring Managers from top biotech, pharma, medical device and diagnostics companies in the Southern California region.

Candidates with a 4-year degree in the life sciences and a minimum of 2-years of industry related experience are invited to attend. (Equivalent work experience may be considered in lieu of a four-year college degree. PhD and Postdoc candidates welcome.)

Exhibiting companies are recruiting for positions in areas such as: QA/QC, clinical research, engineering, manufacturing, biostatistics, clinical data management, chemistry, regulatory affairs, and research.

Job seekers may register here.

Biotech Beach Career Fair, San Diego, CA September 22, 2011
BioMidwest Career Fair, Chicago, IL October 4, 2011
Pharm Country Career Fair, Bridgewater, NJ October 5, 2011
Biotech Bay Career Fair, Burlingame, CA October 11, 2011
Bio NC Career Fair, Durham, NC October 20, 2011
BioCapital Beach Career Fair, Bethesda, MD November 1, 2011
Genetown Career Fair, Cambridge, MA November 7, 2011

More information about BioSpace's Career Fairs

BioSpace White Paper
Biotech Career Fairs For Job Seekers 101: Control Your Experience
By June Salvati, BioSpace Director of Events and Corporate Services
Company of the day

Dynavax Technologies Corporation
2929 Seventh Street, Suite 100
Berkeley, California 94710 U.S.A.
Phone: 510-848-5100 Fax: 510-848-1379

Dynavax Technologies Corporation is a clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious and inflammatory diseases. Our clinical-stage product candidates include: Phase 3 HEPLISAV™ Hepatitis B Vaccine, Phase 1 Universal Flu Vaccine, Phase 1 Hepatitis C Therapy and Phase 1 Hepatitis B Therapy.

More Company Profiles
Free Resources
FREE Subscription to CAP Today

CAP Today brings monthly business and medical news in the clinical laboratory. CAP Today, the College of American Pathologists' monthly news magazine, is the laboratory community's primary source of information on business and medical news in the clinical laboratory.
Contact Us

Post Your: News | Jobs | Company Profile | Event | Advertising / Sponsorship

BioSpace Inc.
6465 South Greenwood Plaza, Suite 400
Centennial, Colorado 80111 U.S.A.
Phone: 877-277-7585
Fax: 800-595-2929
BioSpace Inc.
90 New Montgomery Street, Suite 414
San Francisco, California 94105 U.S.A.
Phone: 877-277-7585
Fax: 415-576-9217

Send questions and comments to the BioSpace News Beat Team.

Editor & Publisher: Rosemary Do
Editorial & Production Staff: Lana Ho, Suvarna Sheth, Maysa Darwish, Tammy Liu

BioSpace.com - Life. Science. Community.
Legal Notice

• BioSpace is a registered trademark of BioSpace, Inc.
• Please distribute this e-cast freely.
• Credit any excerpts as follows:
Copyright 2011 BioSpace http://www.biospace.com
• While BioSpace and its agents used their best efforts in collecting and preparing the information published herein, we do not assume, and hereby disclaim, any liability for any loss or damage caused by errors or omissions, whether such errors or omissions resulted from negligence, accident or other causes.
Subscribe/Unsubscribe
If someone forwarded this news to you and you'd like to receive your own copy FREE of charge, simply Subscribe here.

Safely unsubscribe from Biospace.com e-mail at any time by managing your account here.



No comments: